ArticleJournal of thoracic disease2018
Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy.
Article in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Using Radiomics and Explainable Ensemble Learning to Predict Radiation Pneumonitis and Survival in NSCLC Patients Post-VMAT.Life (Basel, Switzerland) · 2025Article
- Integrating knowledge-based planning and noncoplanar oblique VMAT arcs: A study of dose to the heart and immune cells in thoracic radiotherapy.Technical innovations & patient support in radiation oncology · 2025Article
- Article
- Endostar acts as a pneumonitis protectant in patients with locally advanced non-small cell lung cancer receiving concurrent chemoradiotherapy.BMC cancer · 2024Article
- Safety of hypofractionated volumetric modulated arc therapy for early breast cancer: A preliminary report.Oncology letters · 2023Article
- Clinicoradiological outcomes after radical radiotherapy for lung cancer in patients with interstitial lung disease.BJR open · 2023Article
- Locally advanced NSCLC: a plea for sparing the ipsilateral normal lung-prospective, clinical trial with DART-bid (dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily) by VMAT.Radiation oncology (London, England) · 2022Article
- Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors.Journal of inflammation research · 2021Article
- Toxicity after volumetric modulated arc therapy for lung cancer: a monocentric retrospective study.Translational lung cancer research · 2021Article
- Radiation-induced lung toxicity - cellular and molecular mechanisms of pathogenesis, management, and literature review.Radiation oncology (London, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew studies to date have assessed the incidence of radiation pneumonitis (RP) in lung cancer patients who have been treated with volumetric modulated arc therapy (VMAT). This study is aimed at reporting the RP incidence rate and the risk factors associated with a symptomatic RP in patients with lung cancer treated with VMAT.
methodsA total of 77 consecutive lung cancer patients treated with VMAT from 2013 through 2015 were reviewed. RP severity was graded according to the Common Terminology Criteria for Adverse Events (CTCEA) v.4. Univariate and multivariate analyses were performed to identify the significant factors associated with RP.
resultsVMAT allowed us to achieve most planning objectives on the target volumes and organs at risk, for PTV V
conclusionsOur data showed that the incidence rate of RP was acceptable in lung cancer patients treated with VMAT. Additionally, we found that V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.